REVCOVI (elapegademase-lvlr)
METABOLIC DISEASE ENZYME REPLACEMENT, SEVERE COMB IMMUNE DEF · ADENOSINE DEAMINASE SEVERE COMBINED IMMUNE DEFICIENCY
CHIESI USA, INC
Drug class
Metabolic Disease Enzyme Replacement, Severe Comb Immune Def
The phrase "Metabolic Disease Enzyme Replacement, Severe Comb Immune Def" is a specialized formulary and compendia classification rather than a standard pharmacological drug class designation. Read more about Metabolic Disease Enzyme Replacement, Severe Comb Immune Def
1 drugs in this class 1 manufacturers
Drugs in Metabolic Disease Enzyme Replacement, Severe Comb Immune Def
Filter & compare in the drug finder →
Opens the drug finder with Metabolic Disease Enzyme Replacement, Severe Comb Immune Def preselected. Add indication or manufacturer filters there.
The phrase "Metabolic Disease Enzyme Replacement, Severe Comb Immune Def" is a specialized formulary and compendia classification rather than a standard pharmacological drug class designation.
It encompasses enzyme replacement therapies, such as pegademase bovine and recombinant elapegademase, indicated specifically for adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID).
These agents function as exogenous substitutes for deficient adenosine deaminase, catabolizing toxic purine metabolites like adenosine and deoxyadenosine to alleviate lymphotoxicity and help reconstitute cellular and humoral immune function.
Clinically, these therapies are primarily utilized to stabilize metabolic and immunological status in infants and children affected by ADA-SCID, often serving as a bridge to definitive treatment options such as hematopoietic stem cell transplantation or gene therapy.
-
studylib.net
The phrase "Metabolic Disease Enzyme Replacement, Severe Comb Immune Def" is a specialized formulary and compendia classification rather than a standard pharmacological drug class designation It encompasses enzyme replacement therapies, such as pegademase bovine and recombinant elapegademase, indicated specifically for adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID)
-
nih.gov
It encompasses enzyme replacement therapies, such as pegademase bovine and recombinant elapegademase, indicated specifically for adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID)
-
nih.gov
These agents function as exogenous substitutes for deficient adenosine deaminase, catabolizing toxic purine metabolites like adenosine and deoxyadenosine to alleviate lymphotoxicity and help reconstitute cellular and humoral immune function
-
nih.gov
These agents function as exogenous substitutes for deficient adenosine deaminase, catabolizing toxic purine metabolites like adenosine and deoxyadenosine to alleviate lymphotoxicity and help reconstitute cellular and humoral immune function Clinically, these therapies are primarily utilized to stabilize metabolic and immunological status in infants and children affected by ADA-SCID, often serving as a bridge to definitive treatment options such as hematopoietic stem cell transplantation or gene ...
-
nih.gov
Clinically, these therapies are primarily utilized to stabilize metabolic and immunological status in infants and children affected by ADA-SCID, often serving as a bridge to definitive treatment options such as hematopoietic stem cell transplantation or gene therapy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.